secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001493152-25-001699
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS final LCD denies coverage for Interpace's PancraGEN test; company to discontinue after Feb 7, 2025
--------------------------------------------------------------------------------

- CMS issued final LCD L39365 establishing non-coverage for PancraGEN, a DNA-based test assessing pancreatic cyst cancer risk.
- Interpace will stop accepting PancraGEN specimens after February 7, 2025; test primarily ordered for Medicare patients.
- PancraGEN has helped over 80,000 patients since 2013; CEO calls decision inconsistent with advancing patient care.
- Company plans restructuring but expects to remain profitable with ThyGeNEXT + ThyraMIR v2 thyroid tests.
- Interpace will consider all remedies against CMS/Novitas regarding the non-coverage decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315225001699/0001493152-25-001699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315225001699/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer